JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
ADNOC Gas Targets Up to $4B Profit in 2026 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
US Judge Dismisses Gautam Adani Criminal Charges 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Add as a preferred source on Google
Merck Group announced on Wednesday, March 24, that it has assigned a new chief financial officer. The company picked Caroline Litchfield to be Robert Davis’s replacement and she will assume her post starting April 1.
Litchfield’s new appointment at the company
As per Reuters, Litchfield has been working for Merck since 1990. At that time, she joined the company as part of its unit in the U.K. Prior to her new assignment as CFO this year, she was in charge of Merck’s treasury, tax and investor relations.
She has also worked in the financial operations section for Merck’s Human Health. This unit is the pharmaceutical firm’s largest business to date.
In any case, she will be succeeding Rob Davis, who will leave his post as CFO. He will be taking over as the company’s new chief executive officer as the current CEO, Ken Frazier, already announced last month that he is retiring in June.
Litchfield’s expected contribution as the new CFO
The new assignments of chief officers also come as Merck is aiming for transformation. It wanted to diversify its offerings and go beyond the immuno-oncology business development. It was mentioned that Litchfield would be a big help in this transition as she takes on part of the responsibilities for this plan.
“Caroline’s appointment as our next CFO is the result of a combination of factors and most importantly, Caroline’s financial expertise, remarkable track record, and leadership as well as our commitment to developing talent and our succession planning for leadership roles,” Kenneth C. Frazier said in a press release.
Davis added, “Caroline’s passion for Merck’s mission and for the patients we serve guides every decision that she makes." He said he is also looking forward to working with Caroline and "to benefit from her expertise and leadership as we chart the course for Merck in the months and years ahead.”
In response to the warm welcome from her colleagues, Caroline Litchfield said that she is very honored to serve Merck as the new CFO. She went on to say that her assignment is even more meaningful as it comes at such a pivotal time when the company is transitioning to improve lives.
